BioCryst Pharmaceuticals | Umsatzkosten



Cost Of Sales Veränderung Datum
Alnylam Pharmaceuticals USD 71.04M 31.78M 2025-03
Chugai Pharma JPY 87.82B 6.48B 2025-03
Daiichi Sankyo JPY 94.34B 34.04B 2025-03
Gilead Sciences USD 1.54B 41M 2025-03
GlaxoSmithKline GBP 1.92B 635M 2025-03
Glaxosmithkline GBP 2.52B 199M 2024-12
Incyte USD 67.8M 14.58M 2025-03
Ionis Pharmaceuticals USD 1000K 2.83M 2025-03
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
PTC Therapeutics USD 12.86M 3.42M 2025-03
Regeneron Pharmaceuticals USD 265.5M 299.9M 2025-03
Roche Holding CHF 4.13B 393.5M 2024-12
Sarepta Therapeutics USD 137.56M 5.26M 2025-03
Ultragenyx Pharmaceutical USD 28.66M 11.77M 2025-03
Vertex Pharmaceuticals USD 423.4M 30.8M 2024-12



BioCryst Pharmaceuticals Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Jul 2025.